Severe piperacillin–tazobactam‐induced hemolysis in a cystic fibrosis patient

Abstract

Piperacillin–tazobactam is one of the most common causes of drug‐induced immune hemolytic anemia ( DIIHA ) and is frequently utilized, especially in patients with cystic fibrosis ( CF ). Here, we report a case of life‐threatening piperacillin–tazobactam‐associated DIIHA in a 30‐year‐old woman with CF and propose management recommendations for piperacillin–tazobactam‐associated DIIHA in CF patients.